Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bicalutamide in AR-Positive Metastatic Triple-Negative Breast Cancer
NCT02348281Phase 2Terminated
- Sponsor
- Fudan University
- Start
- Jan 2015
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bicalutamide in triple-negative breast cancer (TNBC), sponsored by Fudan University. Primary endpoint: Clinical Benefit Rate at 48 weeks. Started Jan 2015; status: terminated.
02
Drugs
bicalutamide
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02348281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02348281.